Table 2.
Case No. | Formalin |
HER-2 IHC score;
P = 0.7713 (6 h-48 h vs 1 wk)1 |
PD-L1 expression (%);
P = 0.46 (6 h-48 h vs 1 wk)1 |
||||||
6 h | 24 h | 48 h | 1 wk | 6 h | 24 h | 48 h | 1 wk | ||
1 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
2 | 10% F | 0 | 0 | 0 | 0 | 10 | 10 | 10 | 1-9 |
3 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
4 | 10% F | 0 | 0 | 0 | 0 | 80 | 80 | 90 | 90 |
5 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1-9 |
6 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
8 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 1-9 | 1-9 |
9 | 10% F | 0 | 0 | 0 | 0 | 0 | 1-9 | 0 | 1-9 |
10 | 10% F | 0 | 0 | 0 | 0 | 40 | 30 | 30 | 40 |
11 | 10% F | 0 | 0 | 0 | 0 | 1-9 | 0 | 10 | 10 |
12 | 10% F | 3+ | 3+ | 3+ | 3+ | 1-9 | 1-9 | 1-9 | 0 |
13 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
14 | 10% F | 1+ | 2+ | 0 | 0 | 100 | 1-9 | 30 | 60 |
15 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
16 | 10% F | 0 | 0 | 0 | 0 | 1-9 | 10 | 1-9 | 1-9 |
17 | 10% F | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
18 | 10% F | 0 | 0 | 0 | 0 | 20 | 60 | 20 | 40 |
19 | 10% F | 0 | 0 | 0 | 0 | 1-9 | 1-9 | 1-9 | 0 |
20 | 10% F | 2+ | 0 | 0 | 0 | 80 | 80 | 20 | 1-9 |
21 | 10% F | 0 | 0 | 0 | 0 | 1-9 | 0 | 1-9 | 1-9 |
22 | 10% F | 1+ | 1+ | 2+ | 2+ | 0 | 0 | 0 | 0 |
23 | 10% NBF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
24 | 10% NBF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
25 | 10% NBF | 0 | 1+ | 2+ | 1+ | 10 | 0 | 10 | 0 |
26 | 10% NBF | 2+ | 2+ | 2+ | 2+ | 0 | 0 | 0 | 0 |
27 | 10% NBF | 2+ | 1+ | 1+ | 3+ | 20 | 70 | 30 | 1-9 |
28 | 10% NBF | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
29 | 10% NBF | 0 | 0 | 0 | 0 | 1-9 | 1-9 | 0 | 1-9 |
30 | 10% NBF | 0 | 0 | 0 | 0 | 100 | 100 | 100 | 100 |
31 | 10% NBF | 3+ | 3+ | 3+ | 3+ | 0 | 1-9 | 10 | 1-9 |
32 | 10% NBF | 0 | 0 | 0 | 0 | 70 | 80 | 90 | 90 |
Simultaneous tests for linear hypotheses based on a linear mixed effects model.
F: Formalin; NBF: Neutral buffered formalin; HER-2: Human epidermal growth factor receptor 2; PD-L1: Programmed death-ligand 1.